WHO ICTRP trial
Clinical trial of Chidamide in combination with Anlotinib for refractory and…
ChiCTR2100048715 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2100048715 |
|---|---|
| Public title | Clinical trial of Chidamide in combination with Anlotinib for refractory and advanced soft tissue sarcoma after failure of standard therapy |
| Scientific title | A single-center, single-arm, open, clinical trial of Chidamide in combination with Anlotinib for refractory and advanced soft tissue sarcoma after failure of standard therapy |
| Primary sponsor | Shanghai Sixth People's Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Phase | 0 |
| Countries | China |
| Conditions | soft tissue sarcoma |
| Interventions | single arm group:Treatment was performed according to the combination regimen of cidabentamine and amlotinib |
| Registration date | Jul 13, 2021 |
| Target size | single arm group:56 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: